(Q36139549)

12 August 2017

1 reference

title

Temozolomide in uterine leiomyosarcomas (English)

1 reference

12 August 2017

0 references

2

Carol Aghajanian

1 reference

12 August 2017

Sibyl Anderson

1

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 July 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

98

1 reference

12 August 2017

issue

1

1 reference

12 August 2017

page(s)

99-103

1 reference

Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.018

Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.018

Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.018

High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the E.O.R.T.C. Soft Tissue and Bone Sarcoma Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.018

Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.018

Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.018

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.018

Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.018

Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.018

Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.018

A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.018

A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.018

10.1016/J.YGYNO.2005.03.018

7 January 2021

Identifiers

DOI

1 reference

release_gdgw4sfbdjcy5npnudjvd4pu64

12 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/gdgw4sfbdjcy5npnudjvd4pu64

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference